Clinical trials: Cardiovascular Disease Acute
Stroke, Acute Stroke
Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke
This is a prospective, multicenter, double-blind, randomized, placebo-controlled, Phase Ib/IIa clinical study to assess the administration of ApTOLL together with endovascular therapy in acute ischemic stroke patients who are…
- Conditions
- Stroke, Acute Stroke, Ischemic Stroke
- Trial name
- NCT04734548
- Testing
- ApTOLL
- Where
- 16 sites in France, Germany and 1 more
- Volunteers
- 151 people
- Sponsor
- aptaTargets S.L.
Pulmonary Embolism
First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism
The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
- Trial name
- NCT03927508
- Testing
- r-tPA, The Bashir™ Endovascular Catheter
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Thrombolex, Inc.
Acute Ischemic Stroke (AIS)
Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).
The primary objective of this study is to collect real-world performance and safety data on the Penumbra System in a patient population with acute ischemic stroke (AIS)
- Trial name
- i-RISE (NCT07107022)
- Testing
- Penumbra System ®
- Where
- 12 sites in Australia, Canada and 3 more
- Volunteers
- 200 people
- Sponsor
- Penumbra Inc.
Atherosclerotic Cardiovascular Disease, Acute Coronary Syndromes
Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort
The goal of this clinical trial is to learn if UDP-003 is safe in healthy human participants and patients, assess the pharmacokinetics (PK)/pharmacodynamics (PD) of UDP-003 in healthy human participants and patients and its…
- Trial name
- CTx-001 (NCT06813339)
- Testing
- UDP-003
- Where
- 3 sites in Australia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Cyclarity Therapeutics, Inc.
Acute Coronary Syndrome
Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.
The purpose of this clinical trial is to study the ability of a radioactive drug called "Technetium Glucarate" to detect whether the cause of chest pain in patients entering the emergency department with no obvious signs of heart…
- Trial name
- NCT00614354
- Testing
- 99mTc-glucarate solution
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Molecular Targeting Technologies, Inc.
Acute Ischemic Stroke
A Single-Arm Objective Performance Criteria Trial for Intracranial Thrombus Aspiration Catheter
This is a prospective multicenter, single-arm objective performance criteria trial to assess the efficacy and safety of the the thrombus aspiration catheter.
- Trial name
- NCT05119647
- Testing
- Thrombus Aspiration Catheter(Ton-bridgeMT)
- Where
- 15 sites in China
- Volunteers
- 124 people
- Sponsor
- Ton-Bridge Medical Tech. Co., Ltd
Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD)
"Discovery2" Study of Using MCG at Emergency Departments
The purpose of this research is to collect the magnetic signals from the heart to identify features that may help Emergency Department (ED) doctors differentiate high and low risk patients for heart related chest pain.
- Conditions
- Acute Coronary Syndromes (ACS), Coronary Artery Disease (CAD), Chest Pain, NSTE-ACS (NSTEMI and UA)
- Trial name
- Discovery2 (NCT07822581)
- Testing
- Magnetocardiography
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- SB Technology, Inc.
Acute Myeloid Leukemia, Multiple Myeloma
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
The purpose of this first-in-man Phase I-IIa study is to evaluate the safety and antitumor activity of autologous CD44v6 CAR T-cells in patients with acute myeloid leukemia (AML) and multiple myeloma (MM).
- Trial name
- NCT04097301
- Testing
- MLM-CAR44.1 T-cells at day 0 Single intravenous infusion
- Where
- 3 sites in Czechia, Italy
- Volunteers
- 8 people
- Sponsor
- AGC Biologics S.p.A.
Aortic Dissection
Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections
The purpose of this study is to determine if the Valiant stent graft is safe and effective in treating patients who have a thoracic dissection.
- Trial name
- NCT01114724
- Testing
- Valiant Thoracic Stent Graft with the Captivia Delivery System
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic Cardiovascular
Acute Decompensated Heart Failure, Sleep Disordered Breathing
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF.
- Trial name
- CAT-HF (NCT01953874)
- Testing
- MV ASV, Optimized Medical Treatment
- Where
- 15 sites in United States, Germany
- Volunteers
- 126 people
- Sponsor
- ResMed
Coronary Artery Disease, Coronary Artery Stenosis
Pre-market Study of the DREAMS 2G Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-III)
BIOSOLVE-III Study is a pre-market, prospective, multi-center trial to assess the acute clinical performance of the DREAMS 2G Drug-Eluting Coronary Scaffold in de novo coronary artery lesions.
- Trial name
- BIOSOLVE-III (NCT02716220)
- Testing
- Percutaneous Coronary Intervention
- Where
- 8 sites in Belgium, Germany and 2 more
- Volunteers
- 61 people
- Sponsor
- Biotronik AG
Acute Ischemic Stroke
Transcranial Ultrasound in Clinical SONothrombolysis
This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue…
- Trial name
- TUCSON (NCT00504842)
- Testing
- MRX-801
- Where
- 14 sites in United States, France
- Volunteers
- 72 people
- Sponsor
- ImaRx Therapeutics
Stroke, Ischemic
LOTUS: Global Acute Stroke Study Utilizing Penumbra System
The primary objective of this study is to demonstrate safety and effectiveness of the Penumbra System in a population with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO).
- Trial name
- LOTUS (NCT04157270)
- Testing
- Penumbra System
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Penumbra Inc.
Graft Rejection
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection
This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.
- Trial name
- NCT00300274
- Testing
- everolimus, mycophenolate mofetil, cyclosporine
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 721 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for…
- Trial name
- NCT05487560
- Testing
- Esomezol Cap
- Where
- South Korea
- Volunteers
- 4,133 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Acute Ischemic Stroke
The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).
- Trial name
- NCT07739160
- Testing
- HRS-4029
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Intracranial Aneurysm, AVM - Cerebral Arteriovenous Malformation
Postmarket Study of Tarvos Microguidewire in Neurovascular Interventional Surgery
This investigation is to evaluate the clinical effectiveness and safety of the Tarvos Microguidewire in the neurovascular interventional surgery.
- Conditions
- Intracranial Aneurysm, AVM - Cerebral Arteriovenous Malformation, AV Fistula, Acute Ischemic Stroke
- Trial name
- NCT07500155
- Testing
- Tarvos Microguidewire
- Where
- China
- Volunteers
- 121 people
- Sponsor
- Keuro MedTech
Heart Diseases, Heart Transplantation
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
The purpose of this study is to assess the safety and efficacy of tacrolimus in de novo heart transplantation.
- Trial name
- NCT00157014
- Testing
- Tacrolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 13 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Astellas Pharma Inc
Hereditary Angioedema
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
This study is being conducted to explore the clinical safety, local tolerability, convenience and effectiveness of self-treatment of hereditary angioedema (HAE) attacks with subcutaneous injections of icatibant.
- Trial name
- EASSI (NCT00997204)
- Testing
- Icatibant
- Where
- 26 sites in Argentina, Austria and 8 more
- Volunteers
- 151 people
- Sponsor
- Shire
Myocardial Infarction, Acute, Coronary Artery Disease
Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy
The study aims to evaluate a modified antiplatelet therapy associated with Firehawk low-dose rapamycin DES in acute myocardial infarction patients treated with complete revascularization strategy.
- Trial name
- TARGET-FIRST (NCT04753749)
- Testing
- Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin), Standard DAPT
- Where
- 40 sites in Austria, France and 4 more
- Volunteers
- 2,248 people
- Sponsor
- MicroPort CRM
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.